FCP
INSY

Fine Capital Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

Fine Capital Partners’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-452,546
Closed -$4.76M – 23
2017
Q1 		$4.76M Buy
+452,546
New +$4.82M 0.46% 21

Other funds holding INSY

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fine Capital Partners's INSY Position: Q2 2017 in Review

Fine Capital Partners sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 452,546 shares — an estimated $4.76M sold.

Fine Capital Partners first reported a position in INSY in Q1 2017 and held it in 1 quarter. The position peaked at $4.76M in Q1 2017. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

  • Fine Capital Partners reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Fine Capital Partners sold 452,546 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $4.76M.
  • Fine Capital Partners first reported a position in Insys Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Fine Capital Partners's Insys Therapeutics, Inc. position peaked at $4.76M in Q1 2017.
  • 118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Fine Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.